On prejudice and facts and choices

Annals of Oncology

Volumn 17, Issue 2, 2006, Pages 185-187

  Kohne C H ^a   Folprecht, G ^b  

^a KLINIKUM OLDENBURG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; ORAL ANTIDIABETIC AGENT; OXALIPLATIN; UFT; VASCULOTROPIN ANTIBODY;

BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DEVICE INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERANCE; EDITORIAL; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; THROMBOSIS;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 31544457662     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj142     Document Type: Editorial

References (25)

1. Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. J Clin Oncol 1998; 16(4): 1358-1362.
2. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94(9): 652-661.
3. Folprecht G, Köhne CH. The role of new agents in the treatment of colorectal cancer. Oncology 2004; 66(1): 1-17.
4. Mueller BU, Skelton J, Callender DP, et al. A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 1992; 10(12): 1943-1948.
5. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatc cancer. J Clin Oncol 1998; 16(9): 2977-2985.
6. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15(1): 110-115.
7. Borner MM, Schöffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38(3): 349-358.
8. Saltz LB. Another study of how to give fluorouracil? J Clin Oncol 2003; 21(20): 3711-3712.
9. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16(1): 301-308.
10. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19(8): 2282-2292.
11. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19(21): 4097-4106.
12. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20(17): 3617-3627.
13. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90(6): 1190-1197.
14. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13(4): 566-575.
15. Ratain MJ. Dear doctor: We really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol 2002; 20(6): 1434-1435.
16. Twelves C, Gollins S, Greve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/ leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 239-245.
17. Folprecht G, Köhne CH. The role of new agents in the treatment of colorectal cancer. Oncology 2004; 66(1): 1-17.
18. Jordan K, Grothey A, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer (ACRC): Results of an interim analysis. Proc Am Soc Clin Oncol 2002; 21: Abstr no. 2225.
19. Köhne CH, de Greve J, Bokemeyer C, et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. J Clin Oncol 2005; 23[15S]: 3525.
20. Hochster HS, Welles L, Hart L, et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. J Clin Oncol 2005; 23 (Suppl.16s): 354 (Abstr no. 3515).
21. Arkenau H, Schmoll HJ, Kubicka S, et al. Infusional 5-fluorouracil/ folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. J Clin Oncol 2005; 23[15S]: 3507.
22. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21(19): 3665-3675.
23. Twelves C. Capecitabine as first-line treatment in colorectal cancer. pooled data from two large, phase III trials. Eur J Cancer 2002; 38 Suppl 2: 15-20.
24. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13(4): 566-575.
25. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15(2): 808-815.